Qure.ai Bags $65 Mn in Series D Funding Led by Lightspeed Venture Partners

The fresh infusion of funds seeks to drive the expansion of Qure.ai's AI-powered healthcare diagnostics solutions in global markets, especially the US.

India’s leading AI diagnostics startup, Qure.ai, has raised $65 million in a Series D funding round led by Lightspeed Venture Partners.

The fresh infusion of funds seeks to drive the expansion of Qure.ai's AI-powered healthcare diagnostics solutions in global markets, especially the US.

The startup aims to enhance its generative AI models and pursue acquisitions to strengthen its capabilities in disease detection.

Other participants in the funding round include 360 ONE Asset Management, Merck Global Health Innovation Fund, and Kae Capital, along with existing investors Novo Holdings, Health Quad, and TeamFund.

Founded in 2016 by Prashant Warier, Qure.ai utilizes AI technology in over 3,000 imaging sites across 90 countries to assist in detecting diseases such as tuberculosis, lung cancer, and stroke.

Many of its AI-based diagnostic tools have received clearance from US and EU regulators.

According to Prashant Warier, CEO and co-founder of Qure.ai, AI is increasingly being adopted to address bottlenecks in healthcare, including drug discovery, patient management, and surgical assistance.

CEO Warier further noted that the new funds will be directed toward expanding AI diagnostics capabilities and increasing the company's presence in the US and other markets.

Qure.ai’s Latest Innovations

Last month, Qure.ai, received 510(k) FDA clearance for its AI-powered chest CT solution, qCT LN Quant. This advanced tool aims to assist radiologists and pulmonologists in quantifying and monitoring lung nodules, potentially enhancing lung cancer care.

qCT LN Quant is designed to analyze lung nodules on non-contrast chest CT scans, tracking their volumetric growth over time. This tool allows clinicians to measure various dimensions of solid lung nodules, including average, short-axis, long-axis, and effective diameters.

"This FDA clearance is a significant milestone for Qure.ai’s mission to enhance lung cancer care in the United States. With qCT LN Quant, we have an advanced solution to evaluate lung nodules on at-risk patient CT scans, providing precise quantitative characterization and tracking volumetric growth over time," stated Bhargava Reddy, Chief Business Officer, Oncology at Qure.ai.

In March, Ludhiana’s Christian Medical College (CMC) Hospital joined hands with Medtronic, a global healthcare technology company, to introduce Qure.ai’s AI-powered advanced stroke care solution.

Last year, Medtronic India partnered with Qure.ai to integrate AI for advanced stroke management in the country. This collaboration combines Medtronic's neuroscience expertise with Qure.ai's AI-enabled innovations to provide comprehensive stroke care solutions.

Stay tuned for more such updates on Digital Health News.